Leerink Swann Expands Strategic Advisors Group
BOSTON-(Business Wire)-September 29, 2009 - The leading healthcare investment bank, Leerink Swann, today announced the continued expansion of its management consultant arm, the Strategic Advisory group, with the addition of three managing directors: Mary Cummins from Boston Consulting Group, Ben Hohn from Monitor and Kraig Schulz from Marakon. All three are located in the firm’s New York office and will be responsible for assisting Leerink’s life sciences and healthcare clients to develop and deliver sustainable improvement in growth and profitability.
“Our new leaders bring decades of experience in advising boards, CEO’s and senior leaders of life sciences companies on the issues that matter most to them and their shareowners,” said Michael A. Jenkins, Senior Managing Director and Head of Strategic Advisory. “We continue to build a team with deep clinical and therapeutic knowledge coupled with broad understanding of the strategic, financial and organizational realities that must be addressed to deliver superior and sustainable performance.”
Leerink Swann’s strategic advisors conduct over 200 engagements per year for life science companies across a range of business opportunities to help inform their strategic and financial decisions and shape their plans for growth. The majority of Leerink Swann’s consultants possess a Ph.D. or MD, and work exclusively on clinically-grounded, market-savvy solutions for their clients’ business and investment decisions. They support clients’ growth needs through unparalleled industry understanding built on industry management experts, exclusive focus on life sciences and healthcare, access to more than 30,000 healthcare experts through the MEDACorp platform—the firm’s proprietary expert network and a close collaboration with the firm’s investment banking research groups.
“I’m delighted to welcome the new leaders to the firm and look forward to leveraging their experience within our advisory practice and enhancing our ability to provide an integrated suite of services to our clients,” said Jeffrey A. Leerink, Chairman and CEO of Leerink Swann. “The firm’s advisors offer services in product and portfolio strategy, R&D strategy, corporate strategy with a special focus on acquisition and licensing which contribute to the firm’s overall approach in providing our clients with the relevant insight into key market and clinical developments.”
About Mary Cummins
Prior to joining Leerink Swann as a managing director, Mary Cummins spent 17 years at The Boston Consulting Group where she was a partner. She started her career with Bain & Company in London. Mary has advised major pharmaceutical and specialty pharmaceutical companies on corporate strategy, M&A, portfolio strategy, operational effectiveness in R&D and organization redesign.
Cummins received her B.A. in electrical engineering from Cambridge College and an M.B.A. from The Wharton School of the University of Pennsylvania.
About Ben Hohn
Prior to joining Leerink Swann as a managing director, Ben Hohn was a partner with the Monitor Group in New York. He advised clients in the life sciences industries focusing on strategic company challenges and commercial and product development as well as corporate strategy and new growth platforms, M&A analyses and licensing and opportunity assessment.
Hohn received his B.A. in economics from Vassar College and an M.B.A. from Boston University.
About Kraig Schulz
Prior to joining Leerink Swann as a managing director, Kraig Schulz was a partner at Marakon Associates where he led the development of the firm’s “customer-back” approach to strategy. This approach uses deep insights about customers’ needs, behavior and willingness to pay as a starting point to identify and resolve companies pressing issues or challenges. Prior to joining Marakon, Schulz was a Senior Partner at the global ad agency Ogilvy and Mather. Kraig used technical expertise in designing and analyzing primary research and helped clients to identify new opportunities in medical products, pharmaceutical distribution, product licensing and pharmaceutical sales and marketing.
Schulz received his B.A. in economics from University of Minnesota and an M.S. in applied economics from University of Arizona.
About Leerink Swann
Leerink Swann a healthcare-focused investment banking firm that provides equity research, corporate finance, strategic advisory and asset management services for institutional, life sciences and high-net-worth clients. Every year since 2001, Institutional Investor has named Leerink Swann “Best of the Boutiques” in several healthcare categories. Through its MEDACorp division, Leerink Swann provides biomedical-consulting services to the institutional investment community. With an internal team of experts and a dedicated external network of academic and community healthcare professionals, MEDACorp assesses the viability of cutting-edge medical technologies, thus giving decision makers the information they need to perform. Leerink Swann is a member of FINRA/SIPC. For more information, visit www.leerink.com
 |
 |
 |
|
||
 |
|
 |
|
||
Search Our News Using Google Search
Can't find what you want? Try using Google:
